Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amyloid Plaque Imaging in Chemotherapy-Induced Cognitive Impairment
NCT02317783Phase 2Terminated
- Sponsor
- University of Utah
- Start
- Jan 2018
- Primary completion
- Sep 2019
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial, sponsored by University of Utah. Primary endpoint: Number of Scans With Abnormal [18F]Flutemetamol Uptake at 30 days. Started Jan 2018; status: terminated.
Beyond the preview
Go deeper on NCT02317783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02317783.